Korea IPO round-up: Samsung Bioepis plans Nasdaq float as Jeju Air files

Samsung Bioepis, the pharmaceutical arm of Korea’s Samsung Group, is planning a highly-anticipated IPO on the Nasdaq in 2016, and has dished out mandates for the listing to four banks.